Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-07, Vol.383 (5), p.498-500
Hauptverfasser:	Ahn, Inhye E, Tian, Xin, Wiestner, Adrian
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Chromosome 17 Chronic lymphocytic leukemia Disease Progression Female Follow-Up Studies Humans Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Lymphatic leukemia Male Middle Aged Mutation p53 Protein Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyrimidines - therapeutic use Survival Analysis Tumor Suppressor Protein p53 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2005943